Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-62,800
Closed -$794K 14077
2025
Q4
$794K Buy
+62,800
New +$926K ﹤0.01% 7935
2025
Q3
Sell
-52,600
Closed -$827K 13919
2025
Q2
$827K Sell
52,600
-13,000
-20% -$197K ﹤0.01% 7511
2025
Q1
$1.25M Buy
65,600
+7,400
+13% +$162K ﹤0.01% 6459
2024
Q4
$1.39M Buy
58,200
+19,300
+50% +$539K ﹤0.01% 6379
2024
Q3
$1.09M Buy
38,900
+16,400
+73% +$463K ﹤0.01% 6705
2024
Q2
$588K Sell
22,500
-55,100
-71% -$1.15M ﹤0.01% 7720
2024
Q1
$1.7M Sell
77,600
-72,800
-48% -$1.56M ﹤0.01% 5846
2023
Q4
$3.5M Buy
150,400
+45,700
+44% +$919K ﹤0.01% 4384
2023
Q3
$2.07M Sell
104,700
-28,500
-21% -$561K ﹤0.01% 5138
2023
Q2
$3.02M Sell
133,200
-33,800
-20% -$681K ﹤0.01% 4465
2023
Q1
$3.28M Sell
167,000
-359,500
-68% -$6.9M ﹤0.01% 4503
2022
Q4
$9.06M Buy
+526,500
New +$9.34M ﹤0.01% 2967

Other funds holding RXO

Citadel Advisors's RXO Position: Q1 2026 in Review

Citadel Advisors increased its RXO (RXO) stake by 49% in Q1 2026, buying an estimated $3.41M and bringing the position to 706,497 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 9 quarters since. 275 funds tracked by Wall St. Rank hold RXO as of Q1 2026.

  • Citadel Advisors held 706,497 shares of RXO worth $10.3M as of Q1 2026.
  • Citadel Advisors bought 232,422 RXO shares in Q1 2026, an estimated $3.41M.
  • RXO made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3211 holding.
  • Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 9 quarters since.
  • 275 funds tracked by Wall St. Rank held RXO as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.